A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies is a PHASE1 clinical asset sponsored by Incyte Corporation in Solid Tumors. SEO and diligence focus: INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.